Praxis Precision Medicines (PRAX) Stock After Vormatrigine POWER1 Miss And POWER2 Pause How Does Valuation Stack Up

Simply Wall St.06-15

Praxis Precision Medicines (PRAX) recently reported mixed Phase 2/3 POWER1 results for its epilepsy candidate vormatrigine. The trial missed its primary endpoint but showed dose dependent secondary ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2643774132?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-06-15 18:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643774132","market":"hk","top_or_hot":-1,"title":"Praxis Precision Medicines (PRAX) Stock After Vormatrigine POWER1 Miss And POWER2 Pause How Does Valuation Stack Up","media":"Simply Wall St.","content":"<div>\n<p>Praxis Precision Medicines (PRAX) recently reported mixed Phase 2/3 POWER1 results for its epilepsy candidate vormatrigine. The trial missed its primary endpoint but showed dose dependent secondary ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prax/praxis-precision-medicines/news/praxis-precision-medicines-prax-stock-after-vormatrigine-pow\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Praxis Precision Medicines (PRAX) Stock After Vormatrigine POWER1 Miss And POWER2 Pause How Does Valuation Stack Up</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPraxis Precision Medicines (PRAX) Stock After Vormatrigine POWER1 Miss And POWER2 Pause How Does Valuation Stack Up\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-15 18:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prax/praxis-precision-medicines/news/praxis-precision-medicines-prax-stock-after-vormatrigine-pow><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Praxis Precision Medicines (PRAX) recently reported mixed Phase 2/3 POWER1 results for its epilepsy candidate vormatrigine. The trial missed its primary endpoint but showed dose dependent secondary ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prax/praxis-precision-medicines/news/praxis-precision-medicines-prax-stock-after-vormatrigine-pow\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BJJMRZ35.SGD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prax/praxis-precision-medicines/news/praxis-precision-medicines-prax-stock-after-vormatrigine-pow","article_id":"2643774132","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prax/praxis-precision-medicines/news/praxis-precision-medicines-prax-stock-after-vormatrigine-pow","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2643774132","pubTimestamp":1781518941,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Praxis Precision Medicines (PRAX) recently reported mixed Phase 2/3 POWER1 results for its epilepsy candidate vormatrigine. The trial missed its primary endpoint but showed dose dependent secondary benefits and acceptable tolerability.\nSee our latest analysis for Praxis Precision Medicines.\nThe latest vormatrigine update appears to have sharpened near term risk perceptions, with the share price down 22.18% over the past 30 days and 12.13% over 90 days, even as the 1 year total shareholder...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4139":"生物科技","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","PRAX":"Praxis Precision Medicines, Inc.","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC"},"translate_title":"Vormatrigine POWER1失误和POWER2暂停后Praxis Precision Medicines(PRAX)股票估值如何叠加","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRAX":1.5},"content_text":"Praxis Precision Medicines (PRAX) recently reported mixed Phase 2/3 POWER1 results for its epilepsy candidate vormatrigine. The trial missed its primary endpoint but showed dose dependent secondary benefits and acceptable tolerability. See our latest analysis for Praxis Precision Medicines. The latest vormatrigine update appears to have sharpened near term risk perceptions, with the share price down 22.18% over the past 30 days and 12.13% over 90 days, even as the 1 year total shareholder return remains very large. Recent news flow has centered on the mixed POWER1 readout, the pause in POWER2 enrollment, and upcoming visibility at the Goldman Sachs Global Healthcare Conference, so current price moves look closely tied to reassessment of the epilepsy pipeline rather than broad market factors. If you are weighing what this kind of clinical news could mean for other CNS and biotech stories, it may be worth scanning 20 top founder-led companies With Praxis Precision Medicines showing a very large 1-year total return but declining 22.18% over the past 30 days, are you seeing a reset that leaves vormatrigine risk better reflected, or is the stock already pricing in future growth? AdvertisementMost Popular Narrative: 40.6% Undervalued The most followed valuation narrative puts Praxis Precision Medicines' fair value at $449.13 versus a last close of $266.58, which is a wide gap for any CNS focused biotech.  Multiple late stage epilepsy programs, including vormatrigine and relutrigine with breakthrough designation in severe genetic epilepsies, create a portfolio effect in a growing CNS innovation cycle. This increases the probability of multiple approvals and a step change in total company earnings over the back half of the decade.  Read the complete narrative. Want to see how this portfolio effect translates into future revenue, margins and earnings power assumptions, including an earnings profile that requires a very rich future earnings multiple? Result: Fair Value of $449.13 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this upbeat undervaluation story still rests on ambitious trial timelines and label assumptions. Delays or narrower outcomes could quickly challenge the current narrative. Find out about the key risks to this Praxis Precision Medicines narrative. Next Steps If this mix of optimism and concern around Praxis Precision Medicines feels familiar, review the numbers promptly and form your own view with the 2 key rewards and 2 important warning signs. Looking for more investment ideas? Praxis may be front of mind today, but you will miss useful context if you do not compare it with other stocks that fit clear, disciplined criteria.  Target potential mispricings by scanning 43 high quality undervalued stocks that pair strong fundamentals with share prices that still look out of sync with their underlying businesses. Prioritize resilience by running through 68 resilient stocks with low risk scores where balance sheets, earnings quality, and risk scores all aim to limit unpleasant surprises. Spot under-the-radar opportunities by focusing on screener containing 20 high quality undiscovered gems that combine solid metrics with relatively limited current attention.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2643774132","isCrawlerRequest":true}